Although the use of hormone replacement therapy for menopause based on estrogens alone increases endometrial cancer risk, several studies indicate that combined therapy with estrogens and progestins is not related to an appreciable excess of endometrial cancer risk, if progestins are given for more than 10 or 14 days in each cycle. Combined therapy, however, may be associated to greater excess in breast cancer incidence as compared to estrogens alone.
Estrogeni e progestinici nella terapia ormonale sostitutiva in menopausa / C. La Vecchia. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 92:3(2001), pp. 209-212.
Estrogeni e progestinici nella terapia ormonale sostitutiva in menopausa
C. La VecchiaPrimo
2001
Abstract
Although the use of hormone replacement therapy for menopause based on estrogens alone increases endometrial cancer risk, several studies indicate that combined therapy with estrogens and progestins is not related to an appreciable excess of endometrial cancer risk, if progestins are given for more than 10 or 14 days in each cycle. Combined therapy, however, may be associated to greater excess in breast cancer incidence as compared to estrogens alone.Pubblicazioni consigliate
I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR




